CAJ | 학술논문

目的：对风湿关节炎患者运用艾拉莫德进行治疗，分析其临床疗效，并探讨其对免疫学指标的影响。方法90例活动期类风湿关节炎患者，分别给予50 mg/d的艾拉莫德片(甲组)，25 mg/d的艾拉莫德片(乙组)及10毫克/周的甲氨蝶呤(丙组)。在6周及12周时，对三组临床疗效及免疫学指标进行观察与评估。结果甲乙丙三组在用药6周后ACR20开始上升，用药12周之后，在ACR20标准上，甲组为53.3%（16/30），乙组为36.7%（11/30)，丙组为50%（15/30），甲组要优于乙组（P＜0.05），甲组与丙组对比差异不显著，不具有统计学意义（P＞0.05）；三组的IgA、IgM以及IgG等免疫学指标均明显改善，而甲乙两组的IgA的改变要显著优于丙组（P＜0.05）。结论作为一种慢作用药，艾拉莫德在治疗类风湿关节炎上的效果显著，此药物能够免疫调节B淋巴细胞，抑制免疫球蛋白产生。
목적：대풍습관절염환자운용애랍막덕진행치료，분석기림상료효，병탐토기대면역학지표적영향。방법90례활동기류풍습관절염환자，분별급여50 mg/d적애랍막덕편(갑조)，25 mg/d적애랍막덕편(을조)급10호극/주적갑안접령(병조)。재6주급12주시，대삼조림상료효급면역학지표진행관찰여평고。결과갑을병삼조재용약6주후ACR20개시상승，용약12주지후，재ACR20표준상，갑조위53.3%（16/30），을조위36.7%（11/30)，병조위50%（15/30），갑조요우우을조（P＜0.05），갑조여병조대비차이불현저，불구유통계학의의（P＞0.05）；삼조적IgA、IgM이급IgG등면역학지표균명현개선，이갑을량조적IgA적개변요현저우우병조（P＜0.05）。결론작위일충만작용약，애랍막덕재치료류풍습관절염상적효과현저，차약물능구면역조절B림파세포，억제면역구단백산생。
Objective To study the efifcacy of iguratimod in treating rheumatoid arthritis(RA) and analysis the change of immunological indexes. Methods Ninety patients with active RA were allocated to 3 groups:iguratimod 50 mg each day, 25 mg each day or 10 mg MTX each week. Clinical and laboratory parameters were analyzed on 6, 12 weeks. Results After 6 weeks, ACR20 started to rise. After 12 weeks, the ACR20 of the three groups were respectively:50 mg/d dosage group was 53.3%(16/30), 25 mg/d dosage group was 36.7%(11/30), the control group was 50%(15/30), ACR20 was signiifcantly higher in 50 mg/d dosage group than in 25 mg/d dosage group(P<0.05), there was no signiifcant difference between the 50 mg/d dosage group and the control group(P>0.05);IgA, IgM and IgG of three groups all improved, and IgA of 50 mg/d dosage group and 25 mg/d dosage group were more significantly improved compared with the control group (P<0.05). Conclusion Iguratimod is effective in the treatment of rheumatoid arthritis and it can inhibit the produce of immunoglobulin.